CorestemChemon Inc. (KOSDAQ: 166480) has divulged compelling revelations from the Phase 3 ALSummit trial of Neuronata-R® (lenzumestrocel) at the prestigious PACTALS 2025 congress in Melbourne, Australia. The trial aims to investigate the potential of this autologous bone marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS), a debilitating neurodegenerative disorder. Led by the eminent Professor Seung-Hyun Kim of Hanyang University Hospital, a luminary in stem cell-based ALS research, the event gathered a consortium of seven distinguished ALS experts from across the globe. Dr. Ryung-A Lee, Head of R&D Innovation at CorestemChemon, introduced the company and provided a succinct overview of the Phase 3 trial outcomes during the inaugural session.
The subsequent session witnessed the formal presentation of the full Phase 3 clinical trial results by Professor Ki-Uk Oh, the principal investigator of the ALSummit trial from the Department of Neurology at the Advanced Regenerative Medicine Center, Hanyang University Hospital. While the overall trial did not meet its primary and secondary endpoints, a silver lining emerged as Neuronata-R® exhibited significant efficacy in patients manifesting slower disease progression. This subgroup showcased notable improvements at the 12-month mark, underscoring the therapy’s potential to preserve vital functions and respiratory capacity in ALS patients, pivotal factors directly tied to enhancing both quality of life and survival rates.
Moreover, the meticulous analysis of biomarkers uncovered sustained reductions in neurofilament light chain (NfL) and MCP-1, indicative of a profound neuroprotective effect. These findings exemplify the critical interplay between neuroprotection and clinical outcomes, accentuating the importance of leveraging biomarkers for patient stratification in the realm of precision medicine for ALS. This approach not only augments therapeutic efficacy but also aligns with the dynamic regulatory landscape governing ALS drug development globally.
CorestemChemon articulated that the outcomes unveiled at PACTALS 2025 represent a pivotal milestone for engaging in regulatory dialogues. The company is strategically poised to convene a Type-C meeting with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025 to deliberate on the dataset and the promising efficacy observed in the biomarker-driven subgroup. Subsequently, CorestemChemon intends to file a Biologics License Application (BLA) within 2026, with a keen focus on pursuing an accelerated approval pathway in consonance with established precedents in the ALS domain, including the FDA’s recent decision concerning Tofersen.
Neuronata-R® distinguishes itself by addressing the intricate pathophysiological mechanisms underpinning ALS through the utilization of MSCs derived from the patient’s own bone marrow. These cells wield potent anti-inflammatory and immunomodulatory properties, serving to shield motor neurons from degeneration. Through paracrine signaling, they release trophic factors, cytokines, and extracellular vesicles that modulate the local microenvironment, thereby curtailing neuroinflammation. By targeting these fundamental pathological processes, Neuronata-R® endeavors to intercept the relentless neurodegenerative cascade afflicting ALS patients.
Developed and commercialized by CorestemChemon Inc. (KOSDAQ: 166480), Neuronata-R® (Lenzumestrocel) stands as a promising autologous MSC therapy tailored for individuals grappling with ALS. Embarking on ALS research in 2002, the company secured MFDS approval for Neuronata-R® in 2014 and has since administered it to over 400 commercial patients and 190 clinical trial participants without any reported serious adverse events linked to treatment. Noteworthy accolades include Orphan Drug Designation granted by both the U.S. FDA in 2018 and the EMA in 2019. CorestemChemon successfully concluded a Phase 2 trial (NCT01363401) in 2014 and wrapped up its Phase 3 trial (NCT04745299) in 2024, with the final Clinical Study Report (CSR) duly submitted to the MFDS.
Amidst the evolving landscape of ALS therapeutics, the unveiling of Neuronata-R®’s Phase 3 efficacy outcomes at PACTALS 2025 heralds a new era in precision medicine for ALS patients. By aligning with regulatory expectations and harnessing the power of biomarkers, CorestemChemon navigates a strategic pathway towards securing accelerated approval, offering a glimmer of hope to those grappling with the relentless progression of ALS.
- Precision medicine approach heralded by Neuronata-R® Phase 3 results
- Biomarker guidance crucial for patient stratification in ALS therapy
- Strategic alignment with regulatory expectations key for accelerated approval
- Neuronata-R® offers a beacon of hope in the landscape of ALS therapeutics
Tags: regulatory, regenerative medicine
Read more on taiwannews.com.tw